Free Trial

United Therapeutics (UTHR) Stock Price, News & Analysis

$272.88
-3.62 (-1.31%)
(As of 05/24/2024 08:50 PM ET)
Today's Range
$270.02
$277.27
50-Day Range
$228.26
$276.50
52-Week Range
$204.44
$279.98
Volume
408,100 shs
Average Volume
458,327 shs
Market Capitalization
$12.10 billion
P/E Ratio
12.90
Dividend Yield
N/A
Price Target
$309.44

United Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
13.4% Upside
$309.44 Price Target
Short Interest
Healthy
9.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.00
Upright™ Environmental Score
News Sentiment
1.08mentions of United Therapeutics in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$37.06 M Sold Last Quarter
Proj. Earnings Growth
10.50%
From $24.20 to $26.74 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.88 out of 5 stars

Medical Sector

35th out of 922 stocks

Pharmaceutical Preparations Industry

10th out of 421 stocks

UTHR stock logo

About United Therapeutics Stock (NASDAQ:UTHR)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

UTHR Stock Price History

UTHR Stock News Headlines

StockNews.com Lowers United Therapeutics (NASDAQ:UTHR) to Buy
Q1 2024 Liquidia Corp Earnings Call
See More Headlines
Receive UTHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/01/2024
Today
5/26/2024
Next Earnings (Estimated)
8/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:UTHR
CUSIP
91307C10
Employees
1,168
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$309.44
High Stock Price Target
$400.00
Low Stock Price Target
$240.00
Potential Upside/Downside
+13.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$984.80 million
Pretax Margin
55.28%

Debt

Sales & Book Value

Annual Sales
$2.33 billion
Cash Flow
$22.10 per share
Book Value
$120.35 per share

Miscellaneous

Free Float
38,812,000
Market Cap
$12.10 billion
Optionable
Optionable
Beta
0.54

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives


UTHR Stock Analysis - Frequently Asked Questions

Should I buy or sell United Therapeutics stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" UTHR shares.
View UTHR analyst ratings
or view top-rated stocks.

What is United Therapeutics' stock price target for 2024?

10 brokerages have issued 12-month price targets for United Therapeutics' stock. Their UTHR share price targets range from $240.00 to $400.00. On average, they anticipate the company's stock price to reach $309.44 in the next year. This suggests a possible upside of 13.4% from the stock's current price.
View analysts price targets for UTHR
or view top-rated stocks among Wall Street analysts.

How have UTHR shares performed in 2024?

United Therapeutics' stock was trading at $219.89 at the start of the year. Since then, UTHR stock has increased by 24.1% and is now trading at $272.88.
View the best growth stocks for 2024 here
.

When is United Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our UTHR earnings forecast
.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) announced its quarterly earnings data on Wednesday, May, 1st. The biotechnology company reported $6.17 earnings per share for the quarter, beating the consensus estimate of $5.63 by $0.54. The biotechnology company had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a net margin of 42.05% and a trailing twelve-month return on equity of 18.72%. The firm's revenue was up 33.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $4.86 earnings per share.

What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO?

64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees.

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.56%), Janus Henderson Group PLC (1.43%), Jane Street Group LLC (0.00%), LSV Asset Management (1.19%), Swedbank AB (0.95%) and Nordea Investment Management AB (0.68%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon and Raymond Dwek.
View institutional ownership trends
.

How do I buy shares of United Therapeutics?

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:UTHR) was last updated on 5/27/2024 by MarketBeat.com Staff

From Our Partners